.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AF01_Tofacitinib.Tofacitinib .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AF01_Tofacitinib.Tofacitinib| name: | Tofacitinib |
| ATC code: | L04AF01 | route: | oral |
| n-compartments | 2 |
Tofacitinib is an oral Janus kinase (JAK) inhibitor used for the treatment of autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. It is approved for use in adults and functions by modulating the immune response.
Healthy adult subjects, single-dose, oral administration.
Vong, C, et al., & Mukherjee, A (2021). Population Pharmacokinetics of Tofacitinib in Patients With Moderate to Severe Ulcerative Colitis. Clinical pharmacology in drug development 10(3) 229–240. DOI:10.1002/cpdd.899 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33513294
Xie, R, et al., & Menon, S (2019). Population pharmacokinetics of tofacitinib in patients with psoriatic arthritis . International journal of clinical pharmacology and therapeutics 57(9) 464–473. DOI:10.5414/CP203516 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31319908
Chang, C, et al., & Mukherjee, A (2024). Tofacitinib pharmacokinetics in children and adolescents with juvenile idiopathic arthritis. CPT: pharmacometrics & systems pharmacology 13(4) 599–611. DOI:10.1002/psp4.13104 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38298058